Amgen Inc. (AMGN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Amgen Inc. (AMGN)

AMGN 336.00

-0.1%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Dr. John M. de Castro who wrote (641)	9/10/1998 3:56:00 PM
From: bocaburgerman	Read Replies (1) of 1906

John, >However, I am very skeptical and would like to see some results in >humans before I got too excited. Axokine is really Regeneron's second generation version of CNTF. REGN conducted human trials using CNTF to treat Lou Gehrig's disease. Unfortunately the trials were halted abruptly due to adverse side effects of the drug. Apparently one of them was weight loss. Did Regeneron mention anything about the CNTF trials in association with Axokine? Thanks, Winston

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next